黄芪甲苷通过IL-23/IL-17信号通路对病毒性心肌炎的干预作用探讨

临床儿科杂志 ›› 2014, Vol. 32 ›› Issue (6): 570-573.

黄芪甲苷通过IL-23/IL-17信号通路对病毒性心肌炎的干预作用探讨

刘丹莉，刘海英，高顺利

南华大学附属第一医院儿科（湖南衡阳　421001）

收稿日期:2013-12-07 出版日期:2014-06-15 发布日期:2014-06-15

Inhibition of viral myocarditis by Astragaloside through IL-23/IL-17 signaling pathway　

LIU Danli, LIU Haiying, GAO Shunli

(Department of Pediatrics, The First Affiliated Hospital, University of South China, Hengyang 421001, Hunan, China)

Received:2013-12-07 Published:2014-06-15 Online:2014-06-15

摘要/Abstract

摘要：

　目的　探讨白介素（IL）-23/IL-17信号通路在病毒性心肌炎（VMC）中的作用及黄芪甲苷的干预效果。方法　将75只雄性BALB/c小鼠随机分为对照组（n=15）、模型组（n=20）、低剂量干预组（n=20）及高剂量干预组（n=20），对照组小鼠腹腔注射0.1 ml病毒培养液，其余三组腹腔接种0.1 ml含1×10² TCID₅₀柯萨奇病毒B₃培养液建立VMC模型。接种后当日，低、高剂量干预组分别以1%、9%黄芪甲苷0.1 ml灌胃，对照组、模型组以0.1 ml羧甲基纤维素钠溶液灌胃，每天1次，共14 d。期间观察各组表现及死亡情况。第15天处死小鼠取心脏及血液标本，HE染色计算心肌病理积分，流式细胞术分析Th17细胞频率，荧光实时定量PCR、Western blotting检测心肌IL-23、IL-17 mRNA及蛋白表达。结果　四组间死亡率差异有统计学意义（P=0.013），对照组死亡率最低。高剂量干预组的心肌病理积分、Th17细胞频率、心肌IL-23和IL-17 mRNA与蛋白表达水平均低于模型组和低剂量干预组，但高于对照组，差异有统计学意义（P均<0.05）；模型组和低剂量干预组均高于对照组，差异有统计学意义（P均<0.05），而模型组和低剂量干预组之间差异无统计学意义（P>0.05）。结论　黄芪甲苷可能通过抑制IL-23/IL-17信号通路发挥抗VMC作用，且具有剂量依赖性。

Abstract: 　Objective　To explore the role of interleukin-23 (IL-23)/interleukin-17 (IL-17) signaling pathway in viral myocarditis (VMC) and evaluate the intervention effect of Aastragaloside. Methods Seventy-five male BALB/c mice were randomly divided into 4 groups, control group (n=15), model group (n=20), low-dose intervention group (n=20) and high-dose intervention group (n=20). Mice in control group were inoculated with 0.1 ml virus cultivation solution intraperitoneally while mice in the other 3 groups were treated with 0.1ml virus cultivation solution containing 1×10² TCID50 coxsackievirus B₃ (CVB₃) to establish VMC model. On the day of inoculation, mice in low- and high-dose intervention groups were intragastrically administered with 0.1 ml of 1% and 9% Astragaloside solution respectively, whereas those in control and model groups were treated with 0.1 ml carboxymethycellulose solution. Astragaloside or carboxymethycellulose was given once a day and continued 15 days. The number of mice death and the performance of mice were recorded in experimental period. All mice were sacrificed on day 15. The heart and blood sample were obtained. Histological cross sections of heart were stained with hematoxylin-eosin and scored for myocardial histopathologic changes under optical microscope. Th17 cells were analyzed by flow cytometry. The mRNA and protein expression levels of myocardial IL-23 and IL-17 were detected by real-time quantitative PCR and Western blotting, respectively. Results The mortality was statistically significant differences among the four groups (P = 0.013), which was the lowest in the control group. The myocardial histopathologic scores, the percen-tage of Th17 cells, as well as expression levels of myocardial IL-23 and IL-17 mRNA and protein were significantly lower in high-dose intervention group than those in model group and low-dose intervention group, but higher than those in control group (P < 0.05). The myocardial histopathologic scores, the percentage of Th17 cells, as well as expression levels of myocardial IL-23 and IL-17 mRNA and protein were significantly higher in model group and low-dose intervention group (P < 0.05). There were no significant difference in the above mentioned indicators between low-dose intervention group and model group (P > 0.05). Conclusions Astragaloside may dose-dependently protect against VMC by inhibiting IL-23/IL-17 signaling pathway.

刘丹莉，刘海英，高顺利. 黄芪甲苷通过IL-23/IL-17信号通路对病毒性心肌炎的干预作用探讨[J]. 临床儿科杂志, 2014, 32(6): 570-573.

LIU Danli,LIU Haiying,GAO Shunli
. Inhibition of viral myocarditis by Astragaloside through IL-23/IL-17 signaling pathway　[J]. , 2014, 32(6): 570-573.

参考文献

[1] Reddy J，Massilamany C，Buskiewicz I，et al. Autoimmunity in viral myocarditis [J]. Curr Opin Rheumatol，2013，25(4)：502-508.
[2] van den Berg WB，McInnes IB. Th17 cells and IL-17 a-focus on immunopathogenesis and immunotherapeutics [J]. Semin Arthritis Rheum，2013，43(2)：158-170.
[3] 王冬梅，王久敏，刘桂芝. IL-23/IL-17 炎性通路的研究进展 [J]. 现代中西医结合杂志，2013，22(6)：674-677.
[4] 李双杰，张召才，陈瑞珍，等. 黄芪甲苷治疗Balb/c小鼠CVB₃病毒性心肌炎疗效研究 [J]. 中华实用中西医杂志，2004，17(5)：681-683.
[5] Otsuka K，Terasaki F，Ikemoto M，et al. Suppression of inflammation in rat autoimmune myocarditis by S100A8/A9 through modulation of the proinflammatory cytokine network [J]. Eur J Heart Fail，2009，11(3)：229-237.
[6] 刘丹莉，刘海英，高顺利. LIGHT在病毒性心肌炎中的表达及意义 [J]. 中国现代医学杂志，2012，22(26)：38-41.
[7] 赵京霞，王燕，底婷婷，等. IL- 23/IL- 17 轴在银屑病免疫发病机制中的作用 [J]. 基础医学与临床，2012，32(4)：453-456.
[8] Yang F，Wu WF，Yan YL，et al. Expression of IL-23/Th17 pathway in a murine model of Coxsackie virus B3-induced viral myocarditis [J]. Virol J，2011，8(3)：301-309.
[9] Fan Y，Weifeng W，Yuluan Y，et al. Treatment with a neutra-lizing anti-murine interleukin-17 antibody after the onset of coxsackievirus b3-induced viral myocarditis reduces myocardium inflammation [J]. Virol J，2011，8(1)：17-24.
[10] 李璞. 黄芪及其制剂药理作用和临床应用 [J]. 北方药学，2013，10(9)：15.
[11] 于小华，张新刚，李双杰，等. 黄芪甲苷对病毒性心肌炎小鼠心肌柯萨奇-腺病毒受体基因表达的影响 [J]. 实用儿科临床杂志，2005，20(3)：215-217.
[12] 罗永姣，刘红英，李双杰. 小鼠柯萨奇 B3病毒性心肌炎心脏炎症细胞因子基因和蛋白表达及黄芪甲苷干预研究 [J]. 中国动脉硬化杂志，2009，17(2)：122-124.